{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.6","value":"88.6"},{"groupId":"OG001","spread":"15.4","value":"91.0"},{"groupId":"OG002","spread":"22.3","value":"87.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"38"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.8","value":"91.1"},{"groupId":"OG001","spread":"15.1","value":"92.3"},{"groupId":"OG002","spread":"19.0","value":"94.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"title":"Prior to Maintenance Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.5","value":"85.8"},{"groupId":"OG001","spread":"15.3","value":"93.4"},{"groupId":"OG002","spread":"18.6","value":"76.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Completion of Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.3","value":"89.2"},{"groupId":"OG001","spread":"15.6","value":"89.9"},{"groupId":"OG002","spread":"18.3","value":"83.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"12 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.7","value":"97.6"},{"groupId":"OG001","spread":"19.0","value":"89.4"},{"groupId":"OG002","spread":"21.0","value":"77.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"24 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.0","value":"92.4"},{"groupId":"OG001","spread":"16.2","value":"89.9"},{"groupId":"OG002","spread":"17.4","value":"81.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"36 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.1","value":"85.3"},{"groupId":"OG001","spread":"18.4","value":"91.3"},{"groupId":"OG002","spread":"27.4","value":"85.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"48 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.6","value":"82.0"},{"groupId":"OG001","spread":"17.9","value":"85.3"},{"groupId":"OG002","spread":"18.4","value":"71.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"60 Months Off Therapy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"111"},{"groupId":"OG002","value":"41"}],"units":"Participants"}],"description":"Global cognitive functioning was measured based on Cognitive Composite Scores from the Bayley III instrument for subjects \\<3 years of age and on estimated IQ scores from the Stanford Binet V instrument for subjects ≥3 years of age. Higher scores indicate better performance. The normative mean is 100 with a standard deviation of 15.","dispersionType":"Standard Deviation","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.","id":"OG002","title":"High-Risk Group"}],"paramType":"MEAN","populationDescription":"Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy","title":"Neurocognitive Performance Related to Global Cognitive Functioning as Measured by Cognitive Composite Scores and Estimated IQ Scores","type":"SECONDARY","unitOfMeasure":"score on a scale"}